This article is more than 5 years old. Information may no longer be current.
Clearside Biomedical obtains $4 million to develop novel injection platform
Click Here to Manage Email Alerts
ATLANTA — Clearside Biomedical has been launched, and the company and Hatteras Venture Partners have secured $4 million in Series A venture financing for the development of a microinjection system for the treatment of macular edema and retinal vein occlusion, according to a news release from Hatteras.
Clearside's microinjection platform is designed to target drug delivery to the suprachoroidal space, posterior segment and retina.
"The Clearside innovative microneedle allows for targeted delivery of drugs and proteins into the suprachoroidal space, which has only been accessible through surgical techniques in the past. In contrast to standard intravitreal injections, this technique potentially represents a more focused therapy for treatment of retinal diseases," Henry Edelhauser, PhD, professor in the department of ophthalmology, Emory University School of Medicine, said in the release.
"In contrast to standard intravitreal injections, this technique potentially represents a more focused therapy for treatment of retinal diseases," Dr. Edelhauser said.
Dr. Edelhauser and Mark Prausnitz, PhD, professor of chemical and biomolecular engineering, Georgia Institute of Technology, discovered the microneedle system during a multiyear collaboration.
Clearside Biomedical is based in Atlanta, with clinical and pre-clinical research facilities in North Carolina.
Daniel White will serve as Clearside Biomedical president and CEO, and Ben Yerxa, PhD, will serve as vice president for research and development.
Drs. Edelhauser and Prausnitz, Emory University and Georgia Tech have financial interests in Clearside Biomedical and its ocular platform.